These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35899052)

  • 1. Zidebactam restores sulbactam susceptibility against carbapenem-resistant
    Cedano J; Baez M; Pasteran F; Montaña SD; Ra G; Fua V; Corso A; Tolmasky ME; Bonomo RA; Ramírez MS
    Front Cell Infect Microbiol; 2022; 12():918868. PubMed ID: 35899052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates.
    Moya B; Barcelo IM; Bhagwat S; Patel M; Bou G; Papp-Wallace KM; Bonomo RA; Oliver A
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848013
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Guo Y; Han R; Jiang B; Ding L; Yang F; Zheng B; Yang Y; Wu S; Yin D; Zhu D; Hu F;
    Microbiol Spectr; 2022 Aug; 10(4):e0185422. PubMed ID: 35862963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of cefepime/zidebactam (WCK 5222) against Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii endemic to New York City medical centres.
    Khan Z; Iregui A; Landman D; Quale J
    J Antimicrob Chemother; 2019 Oct; 74(10):2938-2942. PubMed ID: 31298277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A New Twist: The Combination of Sulbactam/Avibactam Enhances Sulbactam Activity against Carbapenem-Resistant
    Pasteran F; Cedano J; Baez M; Albornoz E; Rapoport M; Osteria J; Montaña S; Le C; Ra G; Bonomo RA; Tolmasky ME; Adams M; Corso A; Ramirez MS
    Antibiotics (Basel); 2021 May; 10(5):. PubMed ID: 34068158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [In vitro synergistic activity of sulbactam in combination with imipenem, meropenem and cefoperazone against carbapenem-resistant Acinetobacter baumannii isolates].
    Turk Dagi H; Kus H; Arslan U; Tuncer I
    Mikrobiyol Bul; 2014 Apr; 48(2):311-5. PubMed ID: 24819268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol: which are the best present and future therapeutic alternatives?
    Le Terrier C; Freire S; Nordmann P; Poirel L
    Eur J Clin Microbiol Infect Dis; 2024 Feb; 43(2):339-354. PubMed ID: 38095831
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Yang Y; Guo Y; Yin D; Zheng Y; Wu S; Zhu D; Hu F
    Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33139291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of Sulbactam-Durlobactam and Comparators Against a National Collection of Carbapenem-Resistant
    Petropoulou D; Siopi M; Vourli S; Pournaras S
    Front Cell Infect Microbiol; 2021; 11():814530. PubMed ID: 35127562
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Karlowsky JA; Hackel MA; McLeod SM; Miller AA
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0078122. PubMed ID: 36005804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of cefepime/zidebactam (WCK 5222) against recent Gram-negative isolates collected from high resistance settings of Greek hospitals.
    Bhagwat SS; Legakis NJ; Skalidis T; Loannidis A; Goumenopoulos C; Joshi PR; Shrivastava R; Palwe SR; Periasamy H; Patel MV; Chatzipanagiotou S;
    Diagn Microbiol Infect Dis; 2021 Jul; 100(3):115327. PubMed ID: 33744624
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Karlowsky JA; Hackel MA; Bouchillon SK; Sahm DF
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32928739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria.
    Livermore DM; Mushtaq S; Warner M; Vickers A; Woodford N
    J Antimicrob Chemother; 2017 May; 72(5):1373-1385. PubMed ID: 28158732
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Rodriguez CH; Brune A; Nastro M; Vay C; Famiglietti A
    J Med Microbiol; 2020 Jul; 69(7):928-931. PubMed ID: 32584214
    [No Abstract]   [Full Text] [Related]  

  • 15. [Evaluation of the efficacy of colistin/sulbactam combination on carbapenem-resistant Acinetobacter baumannii strains].
    Çetinkol Y; Telli M; Altunçekiç Yıldırım A; Çalgın MK
    Mikrobiyol Bul; 2016 Jul; 50(3):460-5. PubMed ID: 27525401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced bacterial killing with colistin/sulbactam combination against carbapenem-resistant Acinetobacter baumannii.
    Bian X; Liu X; Feng M; Bergen PJ; Li J; Chen Y; Zheng H; Song S; Zhang J
    Int J Antimicrob Agents; 2021 Feb; 57(2):106271. PubMed ID: 33352235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mechanism of drug resistance of carbapenems-resistant Acinetobacter baumannii and the application of a combination of drugs in vitro].
    Zhao C; Xie W; Zhang W; Ye Z; Wu H
    Zhonghua Shao Shang Za Zhi; 2014 Apr; 30(2):166-70. PubMed ID: 24989663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced bacterial killing with a combination of sulbactam/minocycline against dual carbapenemase-producing Acinetobacter baumannii.
    Chandran S; Manokaran Y; Vijayakumar S; Shankar BA; Bakthavatchalam YD; Dwarakanathan HT; Yesudason BL; Veeraraghavan B
    Eur J Clin Microbiol Infect Dis; 2023 May; 42(5):645-651. PubMed ID: 36905566
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    McLeod SM; Moussa SH; Hackel MA; Miller AA
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31988095
    [No Abstract]   [Full Text] [Related]  

  • 20. In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii.
    Seifert H; Müller C; Stefanik D; Higgins PG; Miller A; Kresken M
    J Antimicrob Chemother; 2020 Sep; 75(9):2616-2621. PubMed ID: 32516359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.